Glaukos Corp
GKOS116.220USD
-0.420-0.36%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
6.67BMarket Cap
LossP/E TTM
More Details of Glaukos Corp Company
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; and bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders, such as keratoconus or refractive disorders, among others.
Glaukos Corp Info
Ticker SymbolGKOS
Company nameGlaukos Corp
IPO dateJun 25, 2015
CEOBurns (Thomas William)
Number of employees995
Security typeOrdinary Share
Fiscal year-endJun 25
Address1 Glaukos Way
CityALISO VIEJO
Stock exchangeNASDAQ OMX NASDAQ Basic NYSE
CountryUnited States of America
Postal code92656
Phone19493679600
Websitehttps://www.glaukos.com
Ticker SymbolGKOS
IPO dateJun 25, 2015
CEOBurns (Thomas William)
Company Executives of Glaukos Corp
Name
Name/Position
Position
Shareholding
Change
Mr. Thomas William Burns
Mr. Thomas William Burns
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.51M
+0.69%
Mr. David F. Hoffmeister
Mr. David F. Hoffmeister
Independent Director
Independent Director
69.52K
+56.16%
Mr. Mark J. Foley
Mr. Mark J. Foley
Lead Independent Director
Lead Independent Director
56.36K
+3.89%
Ms. Aimee S. Weisner, J.D.
Ms. Aimee S. Weisner, J.D.
Independent Director
Independent Director
49.23K
+4.47%
Mr. Marc A. Stapley
Mr. Marc A. Stapley
Independent Director
Independent Director
36.18K
+6.19%
Dr. Tomas Navratil
Dr. Tomas Navratil
Chief Development Officer
Chief Development Officer
33.32K
-12.37%
Dr. Leana S. Wen, M.D.
Dr. Leana S. Wen, M.D.
Independent Director
Independent Director
--
--
Dr. Gilbert H. (Gil) Kliman, M.D.
Dr. Gilbert H. (Gil) Kliman, M.D.
Independent Director
Independent Director
--
--
Ms. Denice M. Torres, J.D.
Ms. Denice M. Torres, J.D.
Independent Director
Independent Director
--
--
Mr. Joseph E. Gilliam
Mr. Joseph E. Gilliam
President, Chief Operating Officer
President, Chief Operating Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Thomas William Burns
Mr. Thomas William Burns
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.51M
+0.69%
Mr. David F. Hoffmeister
Mr. David F. Hoffmeister
Independent Director
Independent Director
69.52K
+56.16%
Mr. Mark J. Foley
Mr. Mark J. Foley
Lead Independent Director
Lead Independent Director
56.36K
+3.89%
Ms. Aimee S. Weisner, J.D.
Ms. Aimee S. Weisner, J.D.
Independent Director
Independent Director
49.23K
+4.47%
Mr. Marc A. Stapley
Mr. Marc A. Stapley
Independent Director
Independent Director
36.18K
+6.19%
Dr. Tomas Navratil
Dr. Tomas Navratil
Chief Development Officer
Chief Development Officer
33.32K
-12.37%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
Glaucoma
103.53M
83.41%
Corneal Health
20.59M
16.59%
By RegionUSD
Name
Revenue
Proportion
United States
90.52M
72.93%
International
33.60M
27.07%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Glaucoma
103.53M
83.41%
Corneal Health
20.59M
16.59%
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
13.59%
The Vanguard Group, Inc.
10.50%
Wellington Management Company, LLP
6.23%
PRIMECAP Management Company
3.92%
State Street Investment Management (US)
3.66%
Other
62.08%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
13.59%
The Vanguard Group, Inc.
10.50%
Wellington Management Company, LLP
6.23%
PRIMECAP Management Company
3.92%
State Street Investment Management (US)
3.66%
Other
62.08%
Shareholder Types
Shareholders
Proportion
Investment Advisor
47.73%
Investment Advisor/Hedge Fund
35.27%
Hedge Fund
10.16%
Individual Investor
3.30%
Research Firm
2.10%
Pension Fund
2.09%
Bank and Trust
1.33%
Sovereign Wealth Fund
1.32%
Venture Capital
0.64%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
653
61.34M
106.80%
+235.97K
2025Q2
638
61.06M
106.48%
+15.37K
2025Q1
643
60.20M
105.40%
-1.30M
2024Q4
610
59.75M
105.65%
+533.86K
2024Q3
567
57.47M
104.31%
-894.95K
2024Q2
545
56.86M
103.79%
-713.22K
2024Q1
509
54.47M
110.12%
-1.91M
2023Q4
480
53.71M
109.34%
-1.79M
2023Q3
475
52.90M
108.58%
-1.85M
2023Q2
486
51.69M
106.83%
-2.99M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
7.90M
13.77%
+252.68K
+3.31%
Jun 30, 2025
The Vanguard Group, Inc.
6.10M
10.63%
+146.00K
+2.45%
Jun 30, 2025
Wellington Management Company, LLP
3.24M
5.66%
+953.61K
+41.63%
Jun 30, 2025
PRIMECAP Management Company
1.83M
3.19%
+609.52K
+50.02%
Jun 30, 2025
State Street Investment Management (US)
2.09M
3.64%
+105.97K
+5.34%
Jun 30, 2025
AllianceBernstein L.P.
1.25M
2.18%
-25.68K
-2.01%
Jun 30, 2025
Burns (Thomas William)
1.51M
2.63%
+10.26K
+0.69%
Sep 23, 2025
Geode Capital Management, L.L.C.
1.33M
2.32%
+115.53K
+9.51%
Jun 30, 2025
Columbia Threadneedle Investments (US)
1.02M
1.78%
+73.69K
+7.78%
Jun 30, 2025
Westfield Capital Management Company, L.P.
1.17M
2.04%
+83.67K
+7.72%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Invesco S&P SmallCap Health Care ETF
3.09%
Alger Weatherbie Enduring Growth ETF
2.07%
State Street SPDR S&P Health Care Equipment ETF
1.79%
ROBO Global Healthcare Technology & Innovation ETF
1.4%
State Street SPDR S&P 600 Small Cap Growth ETF
0.69%
Vanguard S&P Small-Cap 600 Growth Index Fund
0.65%
iShares S&P Small-Cap 600 Growth ETF
0.64%
iShares U.S. Medical Devices ETF
0.6%
OneAscent Enhanced Small and Mid Cap ETF
0.53%
State Street SPDR S&P SmallCap 600 ESG ETF
0.51%
View more
Invesco S&P SmallCap Health Care ETF
Proportion3.09%
Alger Weatherbie Enduring Growth ETF
Proportion2.07%
State Street SPDR S&P Health Care Equipment ETF
Proportion1.79%
ROBO Global Healthcare Technology & Innovation ETF
Proportion1.4%
State Street SPDR S&P 600 Small Cap Growth ETF
Proportion0.69%
Vanguard S&P Small-Cap 600 Growth Index Fund
Proportion0.65%
iShares S&P Small-Cap 600 Growth ETF
Proportion0.64%
iShares U.S. Medical Devices ETF
Proportion0.6%
OneAscent Enhanced Small and Mid Cap ETF
Proportion0.53%
State Street SPDR S&P SmallCap 600 ESG ETF
Proportion0.51%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Glaukos Corp?
The top five shareholders of Glaukos Corp are:
BlackRock Institutional Trust Company, N.A. holds 7.90M shares, accounting for 13.77% of the total shares.
The Vanguard Group, Inc. holds 6.10M shares, accounting for 10.63% of the total shares.
Wellington Management Company, LLP holds 3.24M shares, accounting for 5.66% of the total shares.
PRIMECAP Management Company holds 1.83M shares, accounting for 3.19% of the total shares.
State Street Investment Management (US) holds 2.09M shares, accounting for 3.64% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 7.90M shares, accounting for 13.77% of the total shares.
The Vanguard Group, Inc. holds 6.10M shares, accounting for 10.63% of the total shares.
Wellington Management Company, LLP holds 3.24M shares, accounting for 5.66% of the total shares.
PRIMECAP Management Company holds 1.83M shares, accounting for 3.19% of the total shares.
State Street Investment Management (US) holds 2.09M shares, accounting for 3.64% of the total shares.
What are the top three shareholder types of Glaukos Corp?
The top three shareholder types of Glaukos Corp are:
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Wellington Management Company, LLP
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Wellington Management Company, LLP
How many institutions hold shares of Glaukos Corp (GKOS)?
As of 2025Q3, 653 institutions hold shares of Glaukos Corp, with a combined market value of approximately 61.34M, accounting for 106.80% of the total shares. Compared to 2025Q2, institutional shareholding has increased by 0.33%.
What is the biggest source of revenue for Glaukos Corp?
In FY2025Q2, the Glaucoma business generated the highest revenue for Glaukos Corp, amounting to 103.53M and accounting for 83.41% of total revenue.
